HomeCompareWBRBF vs PFE

WBRBF vs PFE: Dividend Comparison 2026

WBRBF yields 2.92% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WBRBF wins by $522.4K in total portfolio value
10 years
WBRBF
WBRBF
● Live price
2.92%
Share price
$36.67
Annual div
$1.07
5Y div CAGR
59.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$572.0K
Annual income
$347,982.31
Full WBRBF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — WBRBF vs PFE

📍 WBRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWBRBFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WBRBF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WBRBF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WBRBF
Annual income on $10K today (after 15% tax)
$248.39/yr
After 10yr DRIP, annual income (after tax)
$295,784.96/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, WBRBF beats the other by $273,465.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WBRBF + PFE for your $10,000?

WBRBF: 50%PFE: 50%
100% PFE50/50100% WBRBF
Portfolio after 10yr
$310.8K
Annual income
$187,120.52/yr
Blended yield
60.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

WBRBF
No analyst data
Altman Z
2.1
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WBRBF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWBRBFPFE
Forward yield2.92%6.13%
Annual dividend / share$1.07$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR59.2%13.2%
Portfolio after 10y$572.0K$49.6K
Annual income after 10y$347,982.31$26,258.71
Total dividends collected$528.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WBRBF vs PFE ($10,000, DRIP)

YearWBRBF PortfolioWBRBF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,165$465.22$9,153$693.39+$2.0KWBRBF
2$12,720$772.82$8,593$849.25+$4.1KWBRBF
3$14,920$1,309.92$8,336$1,066.78+$6.6KWBRBF
4$18,250$2,286.11$8,437$1,384.80+$9.8KWBRBF
5$23,689$4,160.68$9,013$1,875.40+$14.7KWBRBF
6$33,382$8,035.08$10,306$2,680.72+$23.1KWBRBF
7$52,566$16,846.94$12,820$4,101.38+$39.7KWBRBF
8$95,715$39,470.31$17,673$6,826.70+$78.0KWBRBF
9$209,348$106,932.73$27,543$12,591.86+$181.8KWBRBF
10$571,985$347,982.31$49,560$26,258.71+$522.4KWBRBF

WBRBF vs PFE: Complete Analysis 2026

WBRBFStock

Wienerberger AG produces and sells bricks, roof tiles, concrete pavers, and pipe systems in Europe. It operates through Wienerberger Building Solutions, Wienerberger Piping Solutions, and North America segments. The company offers clay blocks for exterior walls, load and non-load-bearing interior walls, and partition walls, as well as for infill and separating walls under the Porotherm and POROTON brand names; facing bricks for façades under the Terca brand, and ceramic façade tiles under the Argeton brand for hospitals, schools, factories, and offices; clay roof tiles under the Koramic, Sandtoft, and Tondach brands; vitrified clay pipes and fittings, shafts, and accessories for sewage systems; and concrete and clay pavements for various applications that include pedestrian zones, public spaces in train stations or airports, and private terraces or gardens under the Semmelrock brand name, as well as paving bricks and terrace tiles under the Penter brand. It also provides plastic pipes, pipe systems, and pipe fittings for sewage disposal and rainwater drainage; sanitation and heating technology; and supplying energy, gas, and drinking water under the Pipelife brand. Wienerberger AG was founded in 1819 and is headquartered in Vienna, Austria.

Full WBRBF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this WBRBF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WBRBF vs SCHDWBRBF vs JEPIWBRBF vs OWBRBF vs KOWBRBF vs MAINWBRBF vs JNJWBRBF vs MRKWBRBF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.